Search

Your search keyword '"Colomba, E."' showing total 195 results
Start Over Author "Colomba, E."
195 results on '"Colomba, E."'

3. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice

Author

Lorusso, D, Colombo, N, Herraez, A, Santin, A, Colomba, E, Miller, D, Fujiwara, K, Pignata, S, Baron-Hay, S, Ray-Coquard, I, Shapira-Frommer, R, Kim, Y, Mccormack, M, Massaad, R, Nguyen, A, Zhao, Q, Mckenzie, J, Prabhu, V, Makker, V, Lorusso D., Colombo N., Herraez A. C., Santin A. D., Colomba E., Miller D. S., Fujiwara K., Pignata S., Baron-Hay S. E., Ray-Coquard I. L., Shapira-Frommer R., Kim Y. M., McCormack M., Massaad R., Nguyen A. M., Zhao Q., McKenzie J., Prabhu V. S., Makker V., Lorusso, D, Colombo, N, Herraez, A, Santin, A, Colomba, E, Miller, D, Fujiwara, K, Pignata, S, Baron-Hay, S, Ray-Coquard, I, Shapira-Frommer, R, Kim, Y, Mccormack, M, Massaad, R, Nguyen, A, Zhao, Q, Mckenzie, J, Prabhu, V, Makker, V, Lorusso D., Colombo N., Herraez A. C., Santin A. D., Colomba E., Miller D. S., Fujiwara K., Pignata S., Baron-Hay S. E., Ray-Coquard I. L., Shapira-Frommer R., Kim Y. M., McCormack M., Massaad R., Nguyen A. M., Zhao Q., McKenzie J., Prabhu V. S., and Makker V.

Abstract

Purpose: Lenvatinib and pembrolizumab (LEN+PEMBRO) demonstrated clinically meaningful and statistically significant improvements in efficacy versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer (aEC) in the phase 3 Study 309/KEYNOTE-775. Health-related quality-of-life (HRQoL) is reported. Patients and Methods: Patients were randomly assigned to receive LEN+PEMBRO (n = 411; LEN 20 mg/day; PEMBRO 200 mg Q3W) or TPC (n = 416; doxorubicin 60 mg/m2 Q3W or paclitaxel 80 mg/m2 [weekly, 3 weeks on/1 week off]). Impact of treatment on HRQoL assessed by the global health status/quality of life (GHS/QoL) score of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) was a secondary objective; other scales of the Quality-of-Life Questionnaire (QLQ-C30), EORTC QLQ-Endometrial, 24 questions (EORTC QLQ-EN24), and EuroQoL 5 dimensions, 5 levels (EQ-5D-5L) were exploratory objectives. HRQoL was assessed on day 1 of each cycle. Completion/compliance, change from baseline, time to first and definitive deterioration were assessed. No multiplicity adjustments were applied for HRQoL endpoints. Results: The latest timepoint at which the predefined rates of completion (≥60%) and compliance (≥80%) were met was week 12. HRQoL at week 12 between treatment groups was generally similar. Time to first deterioration symptom scales favoured LEN+PEMBRO for QLQ-C30 dyspnoea, and QLQ-EN24 for poor body image, tingling/numbness, and hair loss; and TPC was favoured for QLQ-C30 pain, appetite loss, and diarrhoea, and QLQ-EN24 muscular pain. While the QLQ-C30 physical functional scale favoured TPC, other functional scales were generally similar between arms. Time to definitive deterioration favoured LEN+PEMBRO on most scales. Conclusion: HRQoL data from Study 309/KEYNOTE-775, with previously published efficacy and safety results, indicate that LEN+PEMBRO has an overall favourable benefit/risk profile versus TPC fo

Published
2023

4. IO-Synthesise RCC: relationship between baseline health-related quality of life and clinical outcomes of nivolumab in patients with previously treated metastatic renal cell carcinoma using pooled real-world data from France and Germany

Author

Bedke, J., primary, Thiery-Vuillemin, A., additional, Grimm, M.O., additional, Mueller-Huesmann, H., additional, Ivanyi, P., additional, von der Heyde, E., additional, Barthélémy, P., additional, Colomba, E., additional, Albiges, L., additional, Vano, Y.A., additional, Ejzykowicz, F., additional, Brellier, F., additional, Herber, M., additional, Grötzinger, S.W., additional, Quentric, C., additional, Bennett, B., additional, Néré, S., additional, Grünwald, V., additional, and Mouillet, G., additional

Published
2023
Full Text
View/download PDF

5. Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group

Author

Guerin, M., primary, Miran, C., additional, Colomba, E., additional, Cabart, M., additional, Herrmann, T., additional, Pericart, S., additional, Maillet, D., additional, Neuzillet, Y., additional, Deleuze, A., additional, Coquan, E., additional, Laramas, M., additional, Thibault, C., additional, Abbar, B., additional, Mesnard, B., additional, Borchiellini, D., additional, Dumont, C., additional, Boughalem, E., additional, Deville, JL., additional, Cancel, M., additional, Saldana, C., additional, Khalil, A., additional, Baciarello, G., additional, Flechon, A., additional, Walz, J., additional, and Gravis, G., additional

Published
2023
Full Text
View/download PDF

6. Spécificités cliniques des tumeurs de vessie n’infiltrant pas le muscle métastatique d’emblée : étude observationnelle multicentrique merinos

Author

Audenet, F., primary, Pignot, G., additional, Rigaud, J., additional, Cancel, M., additional, Maillet, D., additional, Oudard, S., additional, Pouessel, D., additional, Serrate, C., additional, Dumont, C., additional, Borchiellini, D., additional, Barthelemy, P., additional, Boughalem, E., additional, Colomba, E., additional, Huillard, O., additional, Boyle, H., additional, Lefort, F., additional, Schlurmann, F., additional, and Thibault, C., additional

Published
2022
Full Text
View/download PDF

7. 550P Immunoprofiling of mismatch repair-deficient (MMRd) endometrial cancer (EC) patients (pts): Immune checkpoint inhibitor (ICI)-responders (R) versus non-responders (NR)

Author

Grau Béjar, J.F., primary, Yaniz Galende, E., additional, Genestie, C., additional, Scoazec, J-Y., additional, Edmond, E., additional, Le Formal, A., additional, Blanc-Durand, F., additional, Michels, J., additional, Kfoury, M., additional, Morice, P., additional, Pautier, P., additional, Colomba, E., additional, and Leary, A., additional

Published
2022
Full Text
View/download PDF

8. 1405P Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB)

Author

Guillaume, Z., primary, Bayle, A., additional, Pobel, C., additional, Lacroix, L., additional, Vasseur, D., additional, Albiges, L., additional, Colomba, E., additional, Flippot, R., additional, Naoun, N., additional, Patrikidou, A., additional, Goldschmidt, V., additional, Vuagnat, P., additional, Massard, C., additional, Ponce, S., additional, Fizazi, K., additional, Loriot, Y., additional, Baldini, C., additional, Italiano, A., additional, and Bernard-Tessier, A., additional

Published
2022
Full Text
View/download PDF

9. 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)

Author

Martin Romano, P., primary, Roubaud, G., additional, Lavaud, P., additional, Cabart, M., additional, Pages, A., additional, Vasseur, D., additional, Colomba, E., additional, Cousin, S., additional, Toulmonde, M., additional, Grellety, T., additional, Castel Ajgal, Z., additional, Chabanon, R., additional, Parpaleix, A., additional, Buzzatti, G., additional, Fizazi, K., additional, Gomez-Roca, C.A., additional, Italiano, A., additional, Loriot, Y., additional, and Postel-Vinay, S., additional

Published
2022
Full Text
View/download PDF

10. 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial

Author

Colomba, E., primary, Carril Ajuria, L., additional, Dalban, C., additional, Derosa, L., additional, Alves Costa Silva, C., additional, Rassy, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis Mescam, G., additional, Oudard, S., additional, Laguerre, B., additional, Barthelemy, P., additional, Gross Goupil, M., additional, Geoffrois, L., additional, Thiery-Vuillemin, A., additional, Joly Lobbedez, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2022
Full Text
View/download PDF

11. 1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study

Author

Haberstich, M., primary, Pignot, G., additional, Rigaud, J., additional, Cancel, M., additional, Maillet, D., additional, Oudard, S., additional, Pouessel, D., additional, Serrate, C., additional, Campedel, L., additional, Dumont, C., additional, Borchiellini, D., additional, Barthelemy, P., additional, Boughalem, E., additional, Colomba, E., additional, Huillard, O., additional, Boyle, H.J., additional, Lefort, F., additional, Constans Schlurmann, F., additional, Audenet, F., additional, and Thibault, C., additional

Published
2022
Full Text
View/download PDF

12. 1380P High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer

Author

Menssouri, N., primary, Wesseling-Rozendaal, Y., additional, Poiraudeau, L., additional, Helissey, C., additional, Bigot, L., additional, Sabio, J., additional, Ibrahim, T., additional, Nicotra, C., additional, Tselikas, L., additional, Colomba, E., additional, Lavaud, P., additional, Besse, B., additional, Scoazec, J-Y., additional, den Biezen, E., additional, Neerken, S., additional, Fizazi, K., additional, Gautheret, D., additional, van de Wiel, P., additional, and Loriot, Y., additional

Published
2022
Full Text
View/download PDF

14. 20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)

Author

Lorusso, D., primary, Colombo, N., additional, Casado Herraez, A., additional, Santin, A.D., additional, Colomba, E., additional, Miller, D.S., additional, Fujiwara, K., additional, Pignata, S., additional, Baron-Hay, S.E., additional, Ray-Coquard, I.L., additional, Shapira-Frommer, R., additional, Kim, Y.M., additional, McCormack, M., additional, Massaad, R., additional, Martin Nguyen, A., additional, Zhao, Q., additional, McKenzie, J., additional, Prabhu, V.S., additional, and Makker, V., additional

Published
2022
Full Text
View/download PDF

15. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Author

Makker, V, Colombo, N, Casado Herráez, A, Santin, A, Colomba, E, Miller, D, Fujiwara, K, Pignata, S, Baron-Hay, S, Ray-Coquard, I, Shapira-Frommer, R, Ushijima, K, Sakata, J, Yonemori, K, Kim, Y, Guerra, E, Sanli, U, Mccormack, M, Smith, A, Keefe, S, Bird, S, Dutta, L, Orlowski, R, Lorusso, D, Makker, Vicky, Colombo, Nicoletta, Casado Herráez, Antonio, Santin, Alessandro D, Colomba, Emeline, Miller, David S, Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally, Ray-Coquard, Isabelle, Shapira-Frommer, Ronnie, Ushijima, Kimio, Sakata, Jun, Yonemori, Kan, Kim, Yong Man, Guerra, Eva M, Sanli, Ulus A, McCormack, Mary M, Smith, Alan D, Keefe, Stephen, Bird, Steven, Dutta, Lea, Orlowski, Robert J, Lorusso, Domenica, Makker, V, Colombo, N, Casado Herráez, A, Santin, A, Colomba, E, Miller, D, Fujiwara, K, Pignata, S, Baron-Hay, S, Ray-Coquard, I, Shapira-Frommer, R, Ushijima, K, Sakata, J, Yonemori, K, Kim, Y, Guerra, E, Sanli, U, Mccormack, M, Smith, A, Keefe, S, Bird, S, Dutta, L, Orlowski, R, Lorusso, D, Makker, Vicky, Colombo, Nicoletta, Casado Herráez, Antonio, Santin, Alessandro D, Colomba, Emeline, Miller, David S, Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally, Ray-Coquard, Isabelle, Shapira-Frommer, Ronnie, Ushijima, Kimio, Sakata, Jun, Yonemori, Kan, Kim, Yong Man, Guerra, Eva M, Sanli, Ulus A, McCormack, Mary M, Smith, Alan D, Keefe, Stephen, Bird, Steven, Dutta, Lea, Orlowski, Robert J, and Lorusso, Domenica

Abstract

BACKGROUND Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously received at least one platinum-based chemotherapy regimen to receive either lenvatinib (20 mg, administered orally once daily) plus pembrolizumab (200 mg, administered intravenously every 3 weeks) or chemotherapy of the treating physician’s choice (doxorubicin at 60 mg per square meter of body-surface area, administered intravenously every 3 weeks, or paclitaxel at 80 mg per square meter, administered intravenously weekly [with a cycle of 3 weeks on and 1 week off]). The two primary end points were progression-free survival as assessed on blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1, and overall survival. The end points were evaluated in patients with mismatch repair–proficient (pMMR) disease and in all patients. Safety was also assessed. RESULTS A total of 827 patients (697 with pMMR disease and 130 with mismatch repair–deficient disease) were randomly assigned to receive lenvatinib plus pembrolizumab (411 patients) or chemotherapy (416 patients). The median progression-free survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 6.6 vs. 3.8 months; hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.50 to 0.72; P<0.001; overall: 7.2 vs. 3.8 months; hazard ratio, 0.56; 95% CI, 0.47 to 0.66; P<0.001). The median overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 17.4 vs. 12.0 months; hazard ratio for death, 0.68; 95% CI, 0.56 to 0.84; P<0.001; overall: 18.3 vs. 11.4 months; hazard ratio, 0.62; 95% CI, 0.51 to 0.75; P<0.001). Adverse events of grade 3 or higher occurred in 88.9% of the patients who received lenvatinib plus pembr

Published
2022

16. Relationship between seed yield and its component characters in Cenchrus spp.

Author

S. Griffa*, M. Quiroga, A. Ribotta, E. López Colomba, E. Carloni, E. Tommasino, C. Luna and K. Grunber

Subjects
Cenchrus spp., seed production, genetic breeding, path coefficient analysis, Plant culture, SB1-1110
Abstract

Cenchrus setigerus, C. sp., eleven obligate apomictic cultivars and a sexual line of Cenchrus ciliaris L. were studied to determinethe relationship between seed production and its component characters, through principal component analysis, path correlationanalysis and analysis of variance. A completely randomized field design was used. Ten vegetative and reproductivemorphological characters were measured. Seed production was influenced directly by panicle weight and indirectly by paniclelength, 1000 seed weight, length and width of flag leaf lamina and length of flag leaf sheath. Panicle weight showed highheritability and variability among genotypes. Hence, panicle weight can be considered a selection criterion to obtain increasedseed production in Cenchrus. The cultivar Lucero INTA PEMAN exhibited the highest panicle weight and, therefore, greatestseed production, which makes it suitable for selection as parental cultivar to obtain new germplasm in Cenchrus with high seedyield.

Published
2012

17. Morphological evaluation of buffelgrass cultivar 'Lucero INTA-PEMAN' in drought conditions

Author

GRIFFA, S., RIBOTTA, A, LUNA, C, BOLLATI, G, LÓPEZ COLOMBA, E., TOMMASINO, E, CARLONI, E, QUIROGA, M., and GRUNBERG, K

Subjects
Cenchrus ciliaris, morphologic characters, drought., Agriculture, Agriculture (General), S1-972
Abstract

In searching for new cultivars that are better adapted to edapho-climatic constraints existing in northwestern Argentina, mainly drought and salinity stress, a hybrid of buffelgrass (Cenchrus ciliaris L.) named Lucero INTA PEMAN was obtained by controlled crosses at the Instituto de Fitopatología y Fisiología Vegetal, INTA. The objective was to morphologically evaluate and compare Cenchrus ciliaris cv Lucero with Texas-4464, Biloela and Molopo cultivars in Dean Funes (North of the Province of Córdoba, Argentina) under drought field conditions using a randomized complete block design with three replications in two crop cycles (2006/2007 and 2007/2008) considering one-year plant and re-growth as ontogenic stages of the plant, respectively. Thirteen morphological characters were analyzed by ANOVA and DGC testing (p

Published
2011

18. Evaluación morfológica del cultivar de buffelgrass 'Lucero INTA-PEMAN' en condiciones de sequía

Author

GRUNBERG, K, QUIROGA, M, CARLONI, E, TOMMASINO, E, BOLLATI, G, LÓPEZ COLOMBA, E, LUNA, C, RIBOTTA, A, and GRIFFA, S

Subjects
Cenchrus ciliaris, caracteres morfológicos, estrés por sequía, Agriculture, Agriculture (General), S1-972
Abstract

En la búsqueda de nuevos cultivares nacionales mejor adaptados a las restricciones edafo-climáticas presentes en el noroeste argentino, principalmente estrés por sequía y salinidad, un híbrido de buffelgrass (Cenchrus ciliaris L.) denominado Lucero INTA-PEMAN fue obtenido mediante cruzamientos controlados en el Instituto de Fitopatología y Fisiología Vegetal (IFFIVE), INTA. El objetivo fue evaluar morfológicamente al cultivar Lucero en comparación a los cultivares Texas-4464, Biloela y Molopo, en Deán Funes (Norte de Córdoba, Argentina) a campo bajo condiciones de sequía, en un diseño en bloques completos aleatorizados con tres repeticiones y por dos ciclos de cultivo (2006/2007 y 2007/2008), considerándose como estados ontogénicos planta de un año y rebrote, respectivamente. Se analizaron 13 caracteres morfológicos mediante ANAVA y test DGC (p

Published
2011

20. O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775

Author

Makker, V, primary, Colombo, N, additional, Casado Herráez, A, additional, Santin, A, additional, Colomba, E, additional, Miller, D, additional, Fujiwara, K, additional, Pignata, S, additional, Baron-Hay, S, additional, Ray-Coquard, I, additional, Shapira, R, additional, Ushijima, K, additional, Sakata, J, additional, Yonemori, K, additional, Kim, YM, additional, Guerra, EM, additional, Sanli, UA, additional, Mccormack, M, additional, Huang, J, additional, and Smith, AD, additional

Published
2021
Full Text
View/download PDF

21. O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors

Author

Makker, V, primary, Colombo, N, additional, Casado Herráez, A, additional, Santin, A, additional, Colomba, E, additional, Miller, D, additional, Fujiwara, K, additional, Pignata, S, additional, Banerjee, S, additional, Monk, B, additional, Ushijima, K, additional, Penson, R, additional, Kristeleit, R, additional, Fabbro, M, additional, Orlando, M, additional, Mackay, H, additional, Ren, M, additional, Orlowski, R, additional, Dutta, L, additional, and Lorusso, D, additional

Published
2021
Full Text
View/download PDF

22. Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

Author

Pommeret, F., primary, Colomba, J., additional, Bigenwald, C., additional, Laparra, A., additional, Bockel, S., additional, Bayle, A., additional, Michot, J.-M., additional, Hueso, T., additional, Albiges, L., additional, Tiberghien, P., additional, Marot, S., additional, Jary, A., additional, Lacombe, K., additional, Barlesi, F., additional, Griscelli, F., additional, and Colomba, E., additional

Published
2021
Full Text
View/download PDF

23. 145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775)

Author

Colombo, N, primary, Lorusso, D, additional, Santin, AD, additional, Kim, YM, additional, Herráez, AC, additional, Yonemori, K, additional, Fujiwara, K, additional, Colomba, E, additional, Miller, DS, additional, Pignata, S, additional, Monk, BJ, additional, Guerra, EM, additional, Kristeleit, R, additional, Orlando, M, additional, Sanli, UA, additional, Dutta, L, additional, Orlowski, R, additional, Ren, M, additional, and Makker, V, additional

Published
2021
Full Text
View/download PDF

24. 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)

Author

Alves Costa Silva, C., primary, Derosa, L., additional, Dalban, C., additional, Colomba, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis, G., additional, Oudard, S.M., additional, Laguerre, B., additional, Barthelemy, P., additional, Borchiellini, D., additional, Gross-Goupil, M., additional, Geoffrois, L., additional, Rolland, F., additional, Thiery-Vuillemin, A., additional, Joly, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2021
Full Text
View/download PDF

25. 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study

Author

Derosa, L., primary, Alves Costa Silva, C., additional, Dalban, C., additional, Colomba, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis, G., additional, Oudard, S.M., additional, Laguerre, B., additional, Barthelemy, P., additional, Borchiellini, D., additional, Gross-Goupil, M., additional, Geoffrois, L., additional, Rolland, F., additional, Thiery-Vuillemin, A., additional, Joly, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2021
Full Text
View/download PDF

26. 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

Author

Colombo, N., primary, Lorusso, D., additional, Herráez, A. Casado, additional, Santin, A.D., additional, Colomba, E., additional, Miller, D.S., additional, Fujiwara, K., additional, Pignata, S., additional, Floquet, A., additional, Monk, B.J., additional, Banerjee, S., additional, Penson, R.T., additional, Kristeleit, R., additional, Fabbro, M., additional, Orlando, M., additional, Mackay, H., additional, Jensen, E., additional, Dutta, L., additional, Orlowski, R., additional, and Makker, V., additional

Published
2021
Full Text
View/download PDF

27. 1565MO Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: An updated analysis of the OnCovid registry

Author

Pinato, D.J., primary, Patel, M., additional, Lambertini, M., additional, Colomba, E., additional, Pommeret, F., additional, Van Hemelrijick, M., additional, Zambelli, A., additional, Newsom-Davis, T., additional, Salazar, R., additional, Bertuzzi, A., additional, Gaidano, G., additional, Rizzo, G., additional, Patel, G., additional, Felip, E., additional, Prat, A., additional, Aguilar-Company, J., additional, Tabernero, J., additional, Diamantis, N., additional, Gennari, A., additional, and Cortellini, A., additional

Published
2021
Full Text
View/download PDF

28. 603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial

Author

Colomba, E., primary, Jonas, S.F., additional, Eymard, J-C., additional, Delva, R., additional, Brachet, P.E., additional, Neuzillet, Y., additional, Penel, N., additional, Roubaud, G., additional, Bompas, E., additional, Mahammedi, H., additional, Longo, R., additional, Helissey, C., additional, Barthelemy, P., additional, Borchiellini, D., additional, Hasbini, A., additional, Priou, F., additional, Saldana, C., additional, Voog, E., additional, Foulon, S., additional, and Fizazi, K., additional

Published
2021
Full Text
View/download PDF

29. 801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma

Author

Colomba, E., primary, Alexandre, J., additional, Le Teuff, G., additional, Coupez, D., additional, Genestie, C., additional, Ray-Coquard, I.L., additional, Brachet, P.E., additional, Sajous, C., additional, De Percin, S., additional, Fabbro, M., additional, Delanoy, N., additional, Joly, F., additional, Pautier, P., additional, Frenel, J-S., additional, and Leary, A., additional

Published
2021
Full Text
View/download PDF

30. 1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy

Author

Bayle, A., primary, Ouali, K., additional, Colomba, E., additional, Ibrahimi, N., additional, Foulon, S., additional, Gachot, B., additional, Willekens, C., additional, Stoclin, A., additional, Merad, M., additional, Griscelli, F., additional, Sun, R., additional, Ammari, S., additional, Michot, J-M., additional, André, F., additional, Scotté, F., additional, Besse, B., additional, Soria, J-C., additional, Barlesi, F., additional, Albiges, L., additional, and Pommeret, F., additional

Published
2021
Full Text
View/download PDF

31. 655MO A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic germ-cell tumors: The CABA-GCT study

Author

Baciarello, G., primary, Cyrille, S., additional, Gravis, G., additional, Fléchon, A., additional, Chevreau, C.M., additional, Deblock, M., additional, Colomba, E., additional, Lavaud, P., additional, Flippot, R., additional, Malekzadeh, K., additional, Le Teuff, G., additional, and Fizazi, K., additional

Published
2021
Full Text
View/download PDF

34. P182 - IO-Synthesise RCC: relationship between baseline health-related quality of life and clinical outcomes of nivolumab in patients with previously treated metastatic renal cell carcinoma using pooled real-world data from France and Germany

Author

Bedke, J., Thiery-Vuillemin, A., Grimm, M.O., Mueller-Huesmann, H., Ivanyi, P., von der Heyde, E., Barthélémy, P., Colomba, E., Albiges, L., Vano, Y.A., Ejzykowicz, F., Brellier, F., Herber, M., Grötzinger, S.W., Quentric, C., Bennett, B., Néré, S., Grünwald, V., and Mouillet, G.

Published
2023
Full Text
View/download PDF

37. 823P Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study

Author

de La Motte Rouge, T., primary, Bengrine Lefevre, L., additional, Mouret-Reynier, M-A., additional, Asselain, B., additional, Lucas, B., additional, Gavoille, C., additional, Cornila, C., additional, Spaeth, D., additional, Colomba, E., additional, Patsouris, A., additional, Fabbro, M., additional, Chakiba, C., additional, Toussaint, P., additional, Simon, H., additional, Berton, D., additional, Garbay, D., additional, Garnier Tixidre, C., additional, Coeffic, D., additional, Collard, O., additional, and Lefeuvre-Plesse, C., additional

Published
2020
Full Text
View/download PDF

38. Influencia de un complejo viral en rendimiento y contenido de clorofila de dos variedades de batata.

Author

Buxmann, E., Vilanova Perez, A., López Colomba, E., Suasnabar, R., Luque, A., Araujo Vieira de Souza, J. C., and Di Feo, L.

Subjects
SWEET potatoes, FOOD crops, PLANT viruses, CULTIVARS, VIRUS diseases, MERISTEMS
Abstract

Copyright of Revista FAVE is the property of Universidad Nacional del Litoral and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022
Full Text
View/download PDF

43. EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.

Author

de Wit, S, Manicone, M, Rossi, E, Lampignano, R, Yang, L, Zill, B, Rengel-Puertas, A, Ouhlen, M, Crespo, M, Berghuis, AMS, Andree, KC, Vidotto, R, Trapp, EK, Tzschaschel, M, Colomba, E, Fowler, G, Flohr, P, Rescigno, P, Fontes, MS, Zamarchi, R, Fehm, T, Neubauer, H, Rack, B, Alunni-Fabbroni, M, Farace, F, De Bono, J, IJzerman, MJ, Terstappen, LWMM, de Wit, S, Manicone, M, Rossi, E, Lampignano, R, Yang, L, Zill, B, Rengel-Puertas, A, Ouhlen, M, Crespo, M, Berghuis, AMS, Andree, KC, Vidotto, R, Trapp, EK, Tzschaschel, M, Colomba, E, Fowler, G, Flohr, P, Rescigno, P, Fontes, MS, Zamarchi, R, Fehm, T, Neubauer, H, Rack, B, Alunni-Fabbroni, M, Farace, F, De Bono, J, IJzerman, MJ, and Terstappen, LWMM

Abstract

The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch® in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low EpCAM expressing CTC (EpCAMlow CTC). In the EU-FP7 CTC-Trap program, we investigated the presence of EpCAMhigh and EpCAMlow CTC using CellSearch, followed by microfiltration of the EpCAMhigh CTC depleted blood. Blood samples of 108 castration-resistant prostate cancer patients and 22 metastatic breast cancer patients were processed at six participating sites, using protocols and tools developed in the CTC-Trap program. Of the prostate cancer patients, 53% had ≥5 EpCAMhigh CTC and 28% had ≥5 EpCAMlow CTC. For breast cancer patients, 32% had ≥5 EpCAMhigh CTC and 36% had ≥5 EpCAMlow CTC. 70% of prostate cancer patients and 64% of breast cancer patients had in total ≥5 EpCAMhigh and/or EpCAMlow CTC, increasing the number of patients in whom CTC are detected. Castration-resistant prostate cancer patients with ≥5 EpCAMhigh CTC had shorter overall survival versus those with <5 EpCAMhigh CTC (p = 0.000). However, presence of EpCAMlow CTC had no relation with overall survival. This emphasizes the importance to demonstrate the relation with clinical outcome when presence of CTC identified with different technologies are reported, as different CTC subpopulations can have different relations with clinical outcome.

Published
2018

44. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

Author

Colomba, E, Teuff, GL, Eisen, T, Stewart, GD, Fife, K, Larkin, J, Biondo, A, Pickering, L, Srinivasan, A, Boyle, H, Derosa, L, Sternberg, CN, Recine, F, Ralph, C, Saldana, C, Barthélémy, P, Bernhard, JC, Gurney, H, Verhoest, G, Vauleon, E, Bigot, P, Berger, J, Pfister, C, Gravis, G, Rodier, J-M, Culine, S, Caty, A, Rolland, F, Priou, F, Escudier, B, Albiges, L, Eisen, Tim [0000-0001-9663-4873], Stewart, Grant [0000-0003-3188-9140], and Apollo - University of Cambridge Repository

Subjects
non-clear cell RCC, mTOR, chromophobe RCC, anti-angiogenic, VEGF, metastatic
Abstract

$\textbf{Background}$ Treatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. $\textbf{Methods}$ We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan–Meier method. $\textbf{Results}$ 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0–13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4–46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2–10.9) and 22.9 months (95% CI: 17.8–49.2) versus 1.9 months (95% CI: 1.0–6.0) and 3.2 months (95% CI: 2.3–not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55). $\textbf{Conclusion}$ We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results